Core Viewpoint - The company is preparing for the 2024 Annual General Meeting (AGM) to ensure the rights of shareholders and maintain order and efficiency during the meeting [1][2][3] Group 1: Meeting Procedures - Only eligible shareholders, directors, supervisors, senior management, and other attendees can participate in the AGM, and the company reserves the right to refuse entry to those who do not meet the criteria [2] - The meeting will follow the agenda as notified, and no agenda items can be postponed or omitted from voting [2] - Attendees must maintain order and respect the rights of other shareholders during the meeting, with the company authorized to take measures against disruptions [2][3] Group 2: Shareholder Rights - Shareholders have the right to speak, inquire, and vote during the AGM, with a maximum speaking time of five minutes per shareholder [3] - The meeting will be witnessed by a lawyer from a law firm to provide legal opinions on the proceedings [3] Group 3: Financial Performance - The company reported a significant increase in sales revenue, with a 29.7% rise to 194,832 million yuan compared to 150,255 million yuan in the previous year [28][32] - The company managed to reduce its operating loss significantly, with a decrease in net loss attributed to improved sales efficiency and cost control measures [34] - The total assets of the company at the end of 2024 were 1,078,196 million yuan, a decrease from 1,134,287 million yuan in 2023 [28][30] Group 4: Governance and Board Activities - The company completed the election of the fourth board of directors on June 21, 2024, with 14 members, including 5 independent non-executive directors [9][11] - The board held 13 meetings during the reporting period, approving all agenda items without any rejections [10] - The board established four specialized committees to enhance governance efficiency and decision-making [10][12] Group 5: Future Plans - The company plans to apply for financing and credit limits totaling up to 8 billion yuan to support its operational and project development needs [39] - The board aims to strengthen its governance structure and enhance compliance management in 2025 [13]

Meeting Information - The annual general meeting of Shanghai Junshi Biosciences Co., Ltd. is scheduled for June 20, 2025, at 14:30 [4] - The meeting will be held at 15th Floor, No. 6, Lane 100, Pingjia Bridge Road, Pudong New District, Shanghai [4] - Voting will be conducted through a combination of on-site and online methods, with specific time slots for each [4][5] Voting Procedures - Shareholders can vote via the Shanghai Stock Exchange's online voting system during designated trading hours on the day of the meeting [4][5] - The voting period for online voting is from 9:15 to 15:00 on June 20, 2025 [4] - Shareholders must complete identity verification to vote online for the first time [5] Attendance Requirements - Shareholders registered with China Securities Depository and Clearing Corporation Limited by the close of trading on June 12, 2025, are eligible to attend [5][8] - Non-natural person shareholders must provide specific documentation, including a business license copy and a power of attorney if represented by an agent [7][8] Proxy Voting - Shareholders can appoint a proxy to attend the meeting and vote on their behalf, with specific requirements for documentation [7][9] - The proxy must present valid identification and a signed power of attorney from the shareholder [9] Additional Information - The company has provided contact details for inquiries related to the meeting [8] - Shareholders are responsible for their own travel and accommodation expenses [8]

Group 1 - The core viewpoint of the announcement is that the company’s supervisory board has approved changes to certain fundraising project sub-items and adjustments to their amounts, which are expected to enhance the efficiency of fund utilization and accelerate the progress of research and development projects [1][2] - The supervisory board meeting was held on May 29, 2025, with all three supervisors present, confirming that the meeting procedures complied with relevant laws and regulations [1] - The proposal for changes and adjustments was unanimously approved by the supervisory board, with all votes in favor and none against or abstaining [2] Group 2 - The adjustments to the fundraising projects are deemed to align with the company's development interests and do not harm the interests of shareholders, particularly minority shareholders [1] - The proposal will be submitted for approval at the company’s upcoming shareholders' meeting [2]

一、募集资金基本情况 证券代码：688180 证券简称：君实生物 公告编号：临 2025-029 上海君实生物医药科技股份有限公司 关于部分募投项目子项目变更及金额调整的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 募投项目子项目变更及金额调整的具体内容：上海君实生物医药科技股 份有限公司（以下简称"公司"）根据募投项目进展，为提高募集资金使用效率， 拟对公司 2022 年度向特定对象发行 A 股股票募集资金投资项目之"创新药研发 项目"中的部分临床试验子项目及其募集资金投资金额进行调整，"创新药研发 项目"的募集资金投资总金额保持不变。 本事项尚需提交公司股东大会审议。 公司于 2025 年 5 月 29 日召开第四届董事会第九次会议、第四届监事会第七 次会议，审议通过了《关于部分募投项目子项目变更及金额调整的议案》，同意 对公司 2022 年度向特定对象发行 A 股股票募集资金投资项目之"创新药研发项 目"中的部分临床试验子项目及其募集资金投资金额进行调整，募集资金投资总 金额保持不变。本事项不 ...

上海君实生物医药科技股份有限公司 2024 年年度股东大会会议资料 2025 年 6 月 三、会议按照会议通知上所列顺序审议、表决议案。对所有已列入本次大会 议程的议案，股东大会不得以任何理由搁置或不予表决。 四、本次股东大会召开期间，全体出席人员应以维护股东的合法权益、确定 会议的正常秩序和议事效率为原则，不得侵犯其他股东的合法权益，不得扰乱会 议的正常秩序。对于干扰股东大会、寻衅滋事和侵犯股东合法权益的行为，公司 有权采取措施加以制止并及时报告有关部门查处。 五、为维护会场秩序，全体参会人员不应随意走动，手机应调整为静音状态， 参会人员无特殊原因应在大会结束后再离开会场。 六、股东参加股东大会依法享有发言权、质询权、表决权等权利。本次股东 大会召开期间，股东准备在股东大会发言/提问的，应当事先在签到处登记，发 言/提问前应当举手示意，在得到会议主持人的同意后，方可发言/提问；股东临 时要求发言/提问的，需先向会议主持人提出口头申请，经主持人同意后方可发 言/提问。股东发言应围绕会议议题进行，简明扼要。每位股东发言/提问时间原 | 2024 年年度股东大会会议议程 3 | | | --- | --- | | ...

证券代码：688180 证券简称：君实生物 公告编号：临 2025-031 上海君实生物医药科技股份有限公司 关于召开2024年年度股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东大会类型和届次 2024年年度股东大会 （二） 股东大会召集人：董事会 （三） 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 （四） 现场会议召开的日期、时间和地点 召开日期时间：2025 年 6 月 20 日 14 点 30 分 召开地点：上海市浦东新区平家桥路 100 弄 6 号 7 幢 15 层 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 6 月 20 日 至2025 年 6 月 20 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 股东大会召开日期：2025年6月20日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系 ...

证券代码：688180 证券简称：君实生物 公告编号：临 2025-030 上海君实生物医药科技股份有限公司 第四届监事会第七次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 上海君实生物医药科技股份有限公司（以下简称"公司"）第四届监事会第 七次会议通知于2025年5月24日以邮件方式发出。会议于2025年5月29日以现场及 通讯表决的方式召开。 本次会议由监事会主席匡洪燕女士主持，会议应到监事3人，实到监事3人。 会议的召集和召开程序符合《中华人民共和国公司法》和《上海君实生物医药科 技股份有限公司章程》的规定，会议形成的决议合法、有效。 二、监事会会议审议情况 审议通过《关于部分募投项目子项目变更及金额调整的议案》 公司监事会认为：公司部分募投项目子项目变更及金额调整，有利于提高募 集资金使用效率，加快研发项目推进。议案内容及审议程序符合《上市公司监管 指引第2号——上市公司募集资金管理和使用的监管要求》《上海证券交易所科 创板股票上市规则》《上海证券交易所科创板上市公司自律监管 ...

Group 1 - The Hong Kong biopharmaceutical sector experienced a collective rise, with WuXi Biologics (02269.HK) and Junshi Biosciences (01877.HK) leading the gains, both increasing over 9% [1] - Other companies such as WuXi AppTec (02359.HK), Kanglong Chemical (300759.HK), Kelun Pharmaceutical (06821.HK), and Tigermed (03347.HK) also saw increases of 4%-5% [1] Group 2 - A significant ruling by the U.S. International Trade Court on May 28 declared the "day of liberation" tariff policy from the Trump administration unconstitutional, reducing policy uncertainty for Chinese pharmaceutical companies looking to expand overseas [3] - The ruling emphasized that the U.S. Constitution grants Congress exclusive power to regulate trade, limiting presidential authority in economic security matters [3] Group 3 - The first quarter of 2025 saw a surge in License-out transactions, totaling 41 deals worth approximately $36.93 billion, nearing the total for the entire year of 2023 [3] - Notable transactions included 3SBio's $12.5 billion upfront payment plus up to $4.8 billion in milestone payments to Pfizer for a PD-1/VEGF dual antibody drug [3] Group 4 - The upcoming ASCO annual meeting in Chicago is expected to showcase the international competitiveness of Chinese innovative drugs, with 71 studies from Chinese companies selected for oral presentations [4] - Key clinical data will be released by several prominent companies, including Innovent Biologics and China Biologic Products, which may reshape treatment standards for non-small cell lung cancer [4][5] Group 5 - The progress of ADC drugs developed by partners of WuXi Biologics and collaborations between Kelun Pharmaceutical and Merck is also attracting attention [5] - The increasing quantity and quality of results presented by Chinese pharmaceutical companies at top academic platforms like ASCO indicate a recognized research and development capability in oncology [5]

作者 | 哥吉拉 数据支持 | 勾股大数 据（www.gogudata.com） 5月29日，A股主要指数高开高走，截至收盘，沪指涨0.7%报3363点，深证成指涨1.24%，创业板指涨1.37%。全市场近4500股上涨，逾百 股涨停。 板块方面，金融科技、创新药、互联网、半导体等热门板块表现强势，市场情绪相比近日明显提振。 其中，创新药是涨幅最明显的板块之一，睿智医药、舒泰神、益方生物强势斩获20CM涨停，另有十多家医药股涨幅均超过10%，堪称又一轮 暴涨潮。 | 代码 | 名称 | 现价 | 1 9 mm a lond a rither more an a many 143 1994 (310 1 涨跌幅▼ | 年初至今涨跌幅 | 总市值1 | | --- | --- | --- | --- | --- | --- | | 300149 | 睿智医药 | 8.56 c | 20.06% | 33.33% | 43亿 | | 300204 | 舒泰神 | 23.04 c | 20.00% | 210.93% | 110亿 | | 688382 | 益元生物-U | 29.10 c | 20.00% | 11 ...

美国法院叫停特朗普关税政策市场风险偏好回升，港股三大指数持续走高，恒生科技指数大幅上涨 2.46%，恒生指数、国企指数分别上涨1.35%及1.37%，恒指升超300点，市场迎来一波久违小高潮。 | 代码 | 名称 | | 最新价 | 涨跌额 | 涨跌幅 | | --- | --- | --- | --- | --- | --- | | Concession of the control of 800000 | DE CARDE LETTRADE 恒生指数 | 1 | 23573.38 | +315.07 | 1.35% | | 800700 | 恒生科技指数 | | 5301.92 | +127.28 | 2.46% | | 800100 | 国企指数 | | 8559.71 | +115.84 | 1.37% | 盘面上，此前走势不断分化的大型科技股再度集体上涨助力大市向好，其中，美团大涨6.6%，快手涨 近5%，京东涨超4%；此前受关税影响下跌的行业多数出现反弹行情，尤其是生物医药股和苹果概念股 涨幅明显，其中，君实生物大涨近15%，药明生物大涨10%；中资券商股、半导体股、重型机械股、餐 饮股、家电股、 ...